Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab SC vs IV in First-Line Metastatic NSCLC
NCT04956692Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Aug 2021
- Primary completion
- Apr 2023
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 16
01
Overview
A Phase 3 trial of pembrolizumab in non-small cell lung cancer (NSCLC), sponsored by Merck & Co.. Started Aug 2021; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04956692.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04956692.